Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis

Molecular Carcinogenesis

Volumn 52, Issue 9, 2013, Pages 715-725

  Hall, Julie M ^a   Korach, Kenneth S ^b  

^a CAMPBELL UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cell proliferation; CXCL12; CXCR4; Endocrine disrupting chemicals (EDCs); Estrogen receptor; Ovarian cancer

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; CHEMOKINE RECEPTOR CXCR4; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GENISTEIN; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

CELL PROLIFERATION; CXCL12; CXCR4; ENDOCRINE DISRUPTING CHEMICALS (EDCS); ESTROGEN RECEPTOR; OVARIAN CANCER;

CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; ENDOCRINE DISRUPTORS; ESTRADIOL; FEMALE; GENE EXPRESSION; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, CXCR4; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84881613679     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21913     Document Type: Article

References (49)

1. Boon WC, Chow JD, Simpson ER. The multiple roles of estrogens and the enzyme aromatase. Prog Brain Res 2010; 181: 209-232.
2. Conzen SD. Minireview: Nuclear receptors and breast cancer. Mol Endocrinol 2008; 22: 2215-2228.
3. Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol 2010; 28: 4038-4044.
4. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276: 36869-36872.
5. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: The second decade. Cell 1995; 83: 835-839.
6. Safe S, Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 2008; 41: 263-275.
7. Stender JD, Kim K, Charn TH, et al. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 2010; 30: 3943-3955.
8. Levin ER. Membrane oestrogen receptor alpha signalling to cell functions . J Physiol 2009; 587: 5019-5023.
9. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010; 204: 105-114.
10. Henley DV, Korach KS. Physiological effects and mechanisms of action of endocrine disrupting chemicals that alter estrogen signaling. Hormones 2010; 9: 191-205.
11. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: An Endocrine Society scientific statement. Endocr Rev 2009; 30: 293-342.
12. Safe S. Clinical correlates of environmental endocrine disruptors. Trends Endocrinol Metab 2005; 16: 139-144.
13. Soto AM, Sonnenschein C. Environmental causes of cancer: Endocrine disruptors as carcinogens. Nat Rev Endocrinol 2010; 6: 363-370.
14. Yang X, Yang S, McKimmey C, et al. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. Carcinogenesis 2010; 31: 695-702.
15. Fanti P, Sawaya BP, Custer LJ, Franke AA. Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. J Am Soc Nephrol 1999; 10: 864-871.
16. Peterson G, Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ 1996; 7: 1345-1351.
17. Welshons WV, Nagel SC, vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology 2006; 147: S56-S69.
18. Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol 2007; 23: 374-382.
19. Soto AM, Vandenberg LN, Maffini MV, Sonnenschein C. Does breast cancer start in the womb? Basic Clin Pharmacol Toxicol 2008; 102: 125-133.
20. Fernandez SV, Russo J. Estrogen and xenoestrogens in breast cancer. Toxicol Pathol 2010; 38: 110-122.
21. Klotz DM, Hewitt SC, Korach KS, Diaugustine RP. Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: Requirement of estrogen receptor-alpha. Endocrinology 2000; 141: 3430-3439.
22. Hewitt SC, Korach KS. Estrogenic activity of bisphenol A and 2, 2-bis(p-hydroxyphenyl)-1, 1, 1-trichloroethane (HPTE) demonstrated in mouse uterine gene profiles. Environ Health Perspect 2010; 119: 63-70.
23. Watson CS, Jeng YJ, Kochukov MY. Nongenomic signaling pathways of estrogen toxicity. Toxicol Sci 2010; 115: 1-11.
24. Carroll JS, Meyer CA, Song J, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006; 38: 1289-1297.
25. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562-4574.
26. Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci U S A 1005; 102: 11651-11656.
27. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003; 17: 792-803.
28. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007; 292: C987-C995.
29. Rhodes LV, Antoon JW, Muir SE, et al. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer 2010; 9: 295.
30. Rhodes LV, Short SP, Neel N, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 2011; 71: 603-613.
31. Sauve K, Lepage J, Sanchez M, Heveker N, Tremblay A. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 2009; 69: 5793-5800.
32. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-5938.
33. Geisinger KR, Kute TE, Pettenati MJ, et al. Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 1989; 63: 280-288.
34. Schmitt E, Dekant W, Stopper H. Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 2001; 15: 433-439.
35. Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS. Association of urinary bisphenol a concentration with heart disease: Evidence from NHANES 2003/06. PLoS One 2010; 5: e8673.
36. Hinton CV, Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis 2010; 27: 97-105.
37. McLachlan JA. Environmental signaling: What embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev 2001; 22: 319-341.
38. Park SH, Kim KY, An BS, et al. Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38. J Reprod Dev 2009; 55: 23-29.
39. Ptak A, Wróbel A, Gregoraszczuk EL. Effect of bisphenol-A on the expression of selected genes involved in cell cycle and apoptosis in the OVCAR-3 cell line. Toxicol Lett 2011; 202: 30-35.
40. Adewale HB, Jefferson WN, Newbold RR, Patisaul HB. Neonatal bisphenol A exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropin-releasing hormone neurons. Biol Reprod 2009; 81: 690-699.
41. Newbold RR, Jefferson WN, Padilla-Banks E. Prenatal exposure to bisphenol A at environmentally relevant doses adversely affects the murine female reproductive tract later in life. Environ Health Perspect 2009; 117: 879-885.
42. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 2009; 308: 32-38.
43. Lucki NC, Sewer MB. Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression. J Biol Chem 2011; 286: 19399-19409.
44. Rich WM, editor. Gynecologic oncology [Internet]. California: Gynecologic Oncology Associates [cited 2011 Aug 9]. Available from: http://www.gyncancer.com/ovarian-cancer.html
45. Power RF, Mani SK, Codina J, Conneely OM, O'Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991; 254: 1636-1639.
46. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008; 122: 91-99.
47. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol 2006; 103: 226-233.
48. Kwong H, Kulbe H, Wong D, Chakravarty P, Balkwill F. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther 2009; 8: 1893-1905.
49. Righi E, Kashiwagi S, Yuan J, et al. CXCL12/CXCR4 blockade induces multimodal anti-tumor effects and prolongs survival of immunocompetent mice with ovarian cancer. Cancer Res 2011; 71: 5522-5534.